WO2025003130 - DENDRITIC CELLS LOADED WITH LYSATES FROM LATE FERROPTOTIC CELLS TO TREAT CANCER

National phase entry is expected:
Publication Number WO/2025/003130
Publication Date 02.01.2025
International Application No. PCT/EP2024/067800
International Filing Date 25.06.2024
Title **
[English] DENDRITIC CELLS LOADED WITH LYSATES FROM LATE FERROPTOTIC CELLS TO TREAT CANCER
[French] CELLULES DENDRITIQUES CHARGÉES DE LYSATS PROVENANT DE CELLULES FERROPTIQUES TARDIVES POUR LE TRAITEMENT DU CANCER
Applicants **
UNIVERSITEIT GENT
Inventors
KRYSKO, Dmitri V.
SAVIUK, Mariia
Priority Data
23182755.1   30.06.2023   EP
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
译文

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting2012
EPO Filing, Examination, Granting8276
Japan Filing, Examination, Granting2093
South Korea Filing, Examination, Granting1945
USA Filing, Examination, Granting4740
MasterCard Visa
Total: 19,066

The term for entry into the National Phase has expired. This quotation is for informational purposes only

Contact Us
Abstract[English] The present invention relates to the field of immunotherapeutical compositions which can be used to treat cancer. More in particular, the present invention discloses dendritic cells loaded with lysates derived from late ferroptotic cancer cells which are useful to treat cancer.[French] La présente invention se rapporte au domaine de compositions immunothérapeutiques qui peuvent être utilisées pour le traitement du cancer. Plus particulièrement, la présente invention divulgue des cellules dendritiques chargées de lysats dérivés de cellules cancéreuses ferroptotiques tardives qui sont utiles pour le traitement du cancer.